Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 10 INDUSTRY 6 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 213 Carcinoma, Non-Small-Cell Lung 148 Lung Neoplasms 128 Lymphoma 119 Prostatic Neoplasms 115 Leukemia 102 Ovarian Neoplasms 100 Central Nervous System Neoplasms 95 Precursor Cell Lymphoblastic Leukemia-Lymphoma 89 Colorectal Neoplasms 89 Head and Neck Neoplasms 87 Sarcoma 84 Multiple Myeloma 80 Squamous Cell Carcinoma of Head and Neck 73 Rectal Neoplasms 62 Leukemia, Myeloid, Acute 62 Carcinoma, Ovarian Epithelial 61 Uterine Cervical Neoplasms 60 Neoplasm Metastasis 59 Brain Neoplasms 57 Colonic Neoplasms 56 Fallopian Tube Neoplasms 53 Astrocytoma 53 Lymphoma, Large B-Cell, Diffuse 50 Glioblastoma 49 Burkitt Lymphoma 47 Urinary Bladder Neoplasms 46 Neuroblastoma 44 Melanoma 44 Hodgkin Disease 44

Interventions

telotristat ethyl 1 lanreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Interventional × Serotonin Syndrome × Clear all

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡